ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
Saved in:
| Title: | ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. |
|---|---|
| Authors: | Stecklein SR; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA.; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA.; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Kimler BF; Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA., Yoder R; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Schwensen K; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Staley JM; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Khan QJ; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., O'Dea AP; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Nye LE; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Elia M; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Heldstab J; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Home T; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Hyter S; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Isakova K; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Pathak HB; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Godwin AK; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA., Sharma P; The University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, KS, USA. psharma2@kumc.edu.; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. psharma2@kumc.edu. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2023 Mar 06; Vol. 9 (1), pp. 10. Date of Electronic Publication: 2023 Mar 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
